Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 1,820	$ 4,042	$ 8,495	$ 12,453
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	144	2,053	2,951	6,338
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 1,676	$ 1,989	$ 5,544	$ 6,115